A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells

Virology Journal

Volumn 3, Issue , 2006, Pages

  Jaalouk, Diana E ^a,c   Lejeune, Laurence ^a   Couture, Clément ^a   Galipeau, Jacques ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; IONOMYCIN; LUCIFERASE; PHORBOL MYRISTATE; THYMIDINE KINASE; TRANSCRIPTION FACTOR NFAT; VIRUS T ANTIGEN;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; NONHUMAN; REPORTER GENE; RETROVIRUS VECTOR; SUICIDE GENE; T LYMPHOCYTE; TRANSGENE;

CYCLOSPORINE; DEPENDOVIRUS; GENETIC ENGINEERING; HUMANS; INTERLEUKIN-2; JURKAT CELLS; LUCIFERASES; LYMPHOCYTE ACTIVATION; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; RETROVIRIDAE; T-LYMPHOCYTES; TRANSGENES;

SIMPLEXVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33845372639     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-97     Document Type: Article

References (35)

1. Qasim W, Gaspar HB, Thrasher AJ: T cell suicide gene therapy to aid haematopoietic stem cell transplantation. Current gene therapy 2005, 5(1):121-132.
2. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276(5319):1719-1724.
3. Verzeletti S, Bonini C, Marktel S, Nobili N, Ciceri F, Traversari C, Bordignon C: Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Human gene therapy 1998, 9(15):2243-2251.
4. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257(5067):238-241.
5. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92(5):1549-1555.
6. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C: Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nature medicine 2001, 7(7):789-794.
7. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(25):16168-16173.
8. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA: Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. Journal of immunology (Baltimore, Md : 1950) 2005, 174(7):4415-4423.
9. Cooper D, Penny R, Symonds G, Carr A, Gerlach W, Sun LQ, Ely J: A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Human gene therapy 1999, 10(8):1401-1421.
10. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop DK, Nabel GJ: Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(3):1201-1206.
11. Hansen G, McIntire JJ, Yeung VP, Berry G, Thorbecke GJ, Chen L, DeKruyff RH, Umetsu DT: CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. The Journal of clinical investigation 2000, 105(1):61-70.
12. Tarner IH, Slavin AJ, McBride J, Levicnik A, Smith R, Nolan GP, Contag CH, Fathman CG: Treatment of autoimmune disease by adoptive cellular gene therapy. Annals of the New York Academy of Sciences 2003, 998:512-519.
13. Mavilio F, Ferrari G, Rossini S, Nobili N, Bonini C, Casorati G, Traversari C, Bordignon C: Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994, 83(7):1988-1997.
14. Movassagh M, Boyer O, Burland MC, Leclercq V, Klatzmann D, Lemoine FM: Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Human gene therapy 2000, 11(8):1189-1200.
15. Agarwal M, Austin TW, Morel F, Chen J, Bèohnlein E, Plavec I: Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. Journal of virology 1998, 72(5):3720-3728.
16. Elsholtz HP, Mangalam HJ, Potter E, Albert VR, Supowit S, Evans RM, Rosenfeld MG: Two different cis-active elements transfer the transcriptional effects of both EGF and phorbol esters. Science 1986, 234(4783):1552-1557.
17. Cooper LJ, Topp MS, Pinzon C, Plavec I, Jensen MC, Riddell SR, Greenberg PD: Enhanced transgene expression in quiescent and activated human CD8+ T cells. Human gene therapy 2004, 15(7):648-658.
18. Dobie KW, Lee M, Fantes JA, Graham E, Clark AJ, Springbett A, Lathe R, McClenaghan M: Variegated transgene expression in mouse mammary gland is determined by the transgene integration locus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(13):6659-6664.
19. Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ: Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000, 96(1):109-117.
20. Tsukahara T, Agawa H, Matsumoto S, Matsuda M, Ueno S, Yamashita Y, Yamada K, Tanaka N, Kojima K, Takeshita T: Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line. Biochemical and biophysical research communications 2006, 345(3):1099-1107.
21. Farrar JD, Asnagli H, Murphy KM: T helper subset development: roles of instruction, selection, and transcription. The Journal of clinical investigation 2002, 109(4):431-435.
22. Parra E, Varga M, Hedlund G, Kalland T, Dohlsten M: Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding. Molecular and cellular biology 1997, 17(3):1314-1323.
23. Gringhuis SI, de Leij LF, Verschuren EW, Borger P, Vellenga E: Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1. Blood 1997, 90(7):2690-2700.
24. Williams S, Couture C, Gilman J, Jascur T, Deckert M, Altman A, Mustelin T: Reconstitution of T cell antigen receptor-induced Erk2 kinase activation in Lck-negative JCaMI cells by Syk. European journal of biochemistry / FEBS 1997, 245(1):84-90.
25. Morgan AJ, Jacob R: Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane. The Biochemical journal 1994, 300:665-672.
26. Hughes CC, Pober JS: Transcriptional regulation of the interleukin-2 gene in normal human peripheral blood T cells. Convergence of costimulatory signals and differences from transformed T cells. The Journal of biological chemistry 1996, 271(10):5369-5377.
27. Shapiro VS, Mollenauer MN, Weiss A: Nuclear factor of activated T cells and AP-1 are insufficient for IL-2 promoter activation: requirement for CD28 up-regulation of RE/AP. Journal of immunology (Baltimore, Md : 1950) 1998, 161(12):6455-6458.
28. Hooijberg E, Bakker AQ, Ruizendaal JJ, Spits H: NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 2000, 96(2):459-466.
29. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunology today 1992, 13(4):136-142.
30. Zhang PX, Fuleihan RL: Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus. Gene therapy 1999, 6(2):182-189.
31. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87(6):2594-2603.
32. Toes RE, Ossendorp F, Offringa R, Melief CJ: CD4 T cells and their role in antitumor immune responses. The Journal of experimental medicine 1999, 189(5):753-756.
33. Paquin A, Jaalouk DE, Galipeau J: Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Human gene therapy 2001, 12(1):13-23.
34. Northrop JP, Ullman KS, Crabtree GR: Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. The Journal of biological chemistry 1993, 268(4):2917-2923.
35. Jaalouk DE, Eliopoulos N, Couture C, Mader S, Galipeau J: Glucocorticoid-inducible retrovector for regulated transgene expression in genetically engineered bone marrow stromal cells. Human gene therapy 2000, 11(13):1837-1849.